Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m 2
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2021Vol. 42(2), pp. 112–118
Citations Over TimeTop 10% of 2021 papers
Cavan P. O’Kane, Juan Carlo Avalon, Jordan L. Lacoste, Wei Fang, Christopher Bianco, Laura Davisson, Kara Piechowski
Abstract
This study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2 .
Related Papers
- → Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator(2018)42 cited
- → Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery(2015)5 cited
- A new strategy for uncontrollable bleeding after treatment with rivaroxaban or apixaban.(2019)
- → The effects of direct oral anticoagulants apixaban and rivaroxaban on haemostasis tests(2015)1 cited
- → ▼ Apixaban and ▼ rivaroxaban for stroke prevention in AF(2014)1 cited